Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Abstract P132: Promotion of E-cadherin-mediated tumor cell adhesion by COX-2/GSK3b signaling is a targetable mechanism of metastatic breast cancer

Balamurugan Kuppusamy, Saadiya Sehareen, Savitri Krishnamurthy, Shikha Sharana, Wei Tang, Naoto T. Ueno, Stefan Ambs, Dipak K. Poria, Esta Sternecka

Mol Cancer Ther (2021) 20 (12_Supplement): P132.

https://doi.org/10.1158/1535-7163.TARG-21-P132

Published: 01 December 2021

View articletitled, Abstract P132: Promotion of E-cadherin-mediated tumor cell adhesion by COX-2/GSK3b signaling is a targetable mechanism of metastatic breast cancer

Journal Articles

AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients

Xiao Xu, Long Mao, Wanhong Xu, Wei Tang, Xiaoying Zhang, Biao Xi, Rongda Xu, Xin Fang, Jia Liu, Ce Fang, Li Zhao, Xiaobo Wang, Ji Jiang, Pei Hu, Hongyun Zhao, Li Zhang

Mol Cancer Ther (2016) 15 (11): 2586–2597.

https://doi.org/10.1158/1535-7163.MCT-16-0281

Published: 01 November 2016

View articletitled, AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients

Includes: Supplementary data

Journal Articles

Abstract C253: PF-06463922, a novel brain-penetrating small molecule inhibitor of ALK/ROS1 with potent activity against a broad spectrum of ALK resistant mutations in preclinical models in vitro and in vivo.

Mol Cancer Ther (2013) 12 (11_Supplement): C253.

https://doi.org/10.1158/1535-7163.TARG-13-C253

Published: 01 November 2013

View articletitled, Abstract C253: PF-06463922, a novel brain-penetrating small molecule inhibitor of ALK/ROS1 with potent activity against a broad spectrum of ALK resistant mutations in preclinical models in vitro and in vivo.

Journal Articles

Abstract A277: PF-06463922, a novel ROS1/ALK inhibitor, demonstrates sub-nanomolar potency against oncogenic ROS1 fusions and capable of blocking the resistant ROS1^G2032R mutant in preclinical tumor models.

Helen Y. Zou, Lars R. Engstrom, Qiuhua Li, Melissa West Lu, Ruth Wei Tang, Hui Wang, Konstantinos Tsaparikos, Sergei Timofeevski, Justine Lam, Shinji Yamazaki, Wenyue Hu, Hovhannes Gukasyan, Nathan Lee, Ted W. Johnson, Valeria Fantin, Tod Smeal

Mol Cancer Ther (2013) 12 (11_Supplement): A277.

https://doi.org/10.1158/1535-7163.TARG-13-A277

Published: 01 November 2013

View articletitled, Abstract A277: PF-06463922, a novel ROS1/ALK inhibitor, demonstrates sub-nanomolar potency against oncogenic ROS1 fusions and capable of blocking the resistant ROS1G2032R mutant in preclinical tumor models.

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract P132: Promotion of E-cadherin-mediated tumor cell adhesion by COX-2/GSK3b signaling is a targetable mechanism of metastatic breast cancer

AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients

Abstract C253: PF-06463922, a novel brain-penetrating small molecule inhibitor of ALK/ROS1 with potent activity against a broad spectrum of ALK resistant mutations in preclinical models in vitro and in vivo.

Abstract A277: PF-06463922, a novel ROS1/ALK inhibitor, demonstrates sub-nanomolar potency against oncogenic ROS1 fusions and capable of blocking the resistant ROS1^G2032R mutant in preclinical tumor models.

Email alerts

AACR Journals

Update search

Abstract P132: Promotion of E-cadherin-mediated tumor cell adhesion by COX-2/GSK3b signaling is a targetable mechanism of metastatic breast cancer

AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients

Abstract C253: PF-06463922, a novel brain-penetrating small molecule inhibitor of ALK/ROS1 with potent activity against a broad spectrum of ALK resistant mutations in preclinical models in vitro and in vivo.

Abstract A277: PF-06463922, a novel ROS1/ALK inhibitor, demonstrates sub-nanomolar potency against oncogenic ROS1 fusions and capable of blocking the resistant ROS1G2032R mutant in preclinical tumor models.

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

Abstract A277: PF-06463922, a novel ROS1/ALK inhibitor, demonstrates sub-nanomolar potency against oncogenic ROS1 fusions and capable of blocking the resistant ROS1^G2032R mutant in preclinical tumor models.